Rituximab

Research use only, not for human use.

Rituximab anti-CD20) is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM.

Rituximab anti-CD20) is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM.

Rituximab inhibits the proliferation of stimulated human B cells, which is associated with a relative increase of B cells with an activated naive phenotype. Aside from this population shift, there are no major changes in phenotype or cytokine profile of the various B-cell subsets. B cells stimulated in the presence of rituximab induces stronger T-cell proliferation, compared to B cells stimulated in the absence of rituximab. All lymphoma cells tested are equally sensitive to antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-mediated phagocytosis of tumor cells, and rituximab-induced apoptosis. Rituximab induces high CDC killing of follicular lymphoma cells.

A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cures 100% of the animals. Depletion of either NK cells or neutrophils or both in tumor-injected animals does not affect the therapeutic activity of the drug. Similarly, rituximab is able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent.

——

Others

Other Targets

Other Targets

——

——

174722-31-7

148 kDa

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years